Related references
Note: Only part of the references are listed.Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy
C. N. Sternberg et al.
ANNALS OF ONCOLOGY (2013)
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial
A. Bahl et al.
ANNALS OF ONCOLOGY (2013)
Long-term Survival and Biomarker Correlates of Tasquinimod Efficacy in a Multicenter Randomized Study of Men with Minimally Symptomatic Metastatic Castration- Resistant Prostate Cancer
A. J. Armstrong et al.
CLINICAL CANCER RESEARCH (2013)
Systemic Therapy in Men with Metastatic Castration-resistant Prostate Cancer: A Systematic Review
D. A. Loblaw et al.
CLINICAL ONCOLOGY (2013)
Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy
Stephen Harland et al.
EUROPEAN JOURNAL OF CANCER (2013)
Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients With Metastatic Castration-Resistant Prostate Cancer
Karim S. Fizazi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Castration-Resistant Prostate Cancer: AUA Guideline
Michael S. Cookson et al.
JOURNAL OF UROLOGY (2013)
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial
David I. Quinn et al.
LANCET ONCOLOGY (2013)
2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial
Pirkko-Liisa Kellokumpu-Lehtinen et al.
LANCET ONCOLOGY (2013)
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
C. Parker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's Experience
S. Yousuf Zafar et al.
ONCOLOGIST (2013)
Phase 3, Randomized, Placebo-Controlled Study Of Zibotentan (ZD4054) in Patients With Castration-Resistant Prostate Cancer Metastatic to Bone
Joel B. Nelson et al.
CANCER (2012)
American Society of Clinical Oncology Provisional Clinical Opinion: The Integration of Palliative Care Into Standard Oncology Care
Thomas J. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401
William Kevin Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Building better guidelines with BRIDGE-Wiz: development and evaluation of a software assistant to promote clarity, transparency, and implementability
Richard N. Shiffman et al.
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION (2012)
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial
Christopher J. Logothetis et al.
LANCET ONCOLOGY (2012)
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
Karim Fizazi et al.
LANCET ONCOLOGY (2012)
Patients' Expectations about Effects of Chemotherapy for Advanced Cancer
Jane C. Weeks et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
Roberto Pili et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Randomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitriol Versus Docetaxel Plus Prednisone for Patients With Castration-Resistant Prostate Cancer
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Docetaxel-based combination therapy for castration-resistant prostate cancer
M. D. Galsky et al.
ANNALS OF ONCOLOGY (2010)
Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial
Nicholas D. James et al.
BJU INTERNATIONAL (2010)
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian de Bono et al.
LANCET (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer
C. N. Sternberg et al.
ANNALS OF ONCOLOGY (2009)
Integrated Data From 2 Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trials of Active Cellular Immunotherapy With Sipuleucel-T in Advanced Prostate Cancer
Celestia S. Higano et al.
CANCER (2009)
Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs
Peter B. Bach
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Prospective Randomized Study Comparing Docetaxel, Estramustine, and Prednisone With Docetaxel and Prednisone in Metastatic Hormone-Refractory Prostate Cancer
Jean-Pascal Machiels et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study
Dominik R. Berthold et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: A randomized phase II study
Sophie D. Fossa et al.
EUROPEAN UROLOGY (2007)
American society of clinical oncology endorsement of the cancer care Ontario practice guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer
Ethan M. Basch et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer
Michael A. Carducci et al.
CANCER (2007)
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases
Paul Mathew et al.
CLINICAL CANCER RESEARCH (2007)
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology Practice Guideline
D. Andrew Loblaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT investigators
Tomasz M. Beer et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer
Mari Nakabayashi et al.
CANCER (2006)
Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group
Eric Winquist et al.
BMC CANCER (2006)
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer
MR Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: A prospective randomized trial
R Manikandan et al.
UROLOGIA INTERNATIONALIS (2005)
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase III trial (CALGB 9583)
EJ Small et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: A phase III study of the European Organization for Research and Treatment of Cancer Genitourinary Group
SD Fossa et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
